CAR-T Immunotherapy Targeting CD19- ALL

Clinical trial NCT04016129 · RECRUITING

Trial details

NCT number: NCT04016129
Sponsor: Shenzhen Geno-Immune Medical Institute
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Leukemia

Start date: 2025-07-15
Primary completion: 2028-07-15
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.